Migraine – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：164頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Migraine – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Migraine - Pipeline Review, H2 2012', provides an overview of the Migraine therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. 'Migraine - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Migraine.
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Migraine pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Migraine.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Migraine therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Migraine - Pipeline Review, H2 2012', provides an overview of the Migraine therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. 'Migraine - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Migraine.
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Migraine pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Migraine.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Migraine therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Migraine Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Migraine 9
Migraine Therapeutics under Development by Companies 11
Migraine Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Migraine Therapeutics – Products under Development by Companies 21
Migraine Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Migraine Therapeutics Development 25
Vyteris, Inc. 25
Eli Lilly and Company 26
BioDelivery Sciences International, Inc. 27
Merck & Co., Inc. 28
Vectura Group plc 29
Alexza Pharmaceuticals, Inc. 30
Biofrontera AG 31
Novartis AG 32
Axcan Pharma Inc. 33
Dr. Reddy's Laboratories Limited 34
Teva Pharmaceutical Industries Limited 35
NuPathe Inc. 36
Capnia, Inc. 37
IntelGenx Technologies Corp. 38
Lupin Limited 39
NovaDel Pharma, Inc. 40
Paladin Labs Inc. 41
MAP Pharmaceuticals, Inc. 42
POZEN Inc. 43
Asterand plc. 44
Genizon BioSciences, Inc. 45
Choongwae Pharma Corp 46
Orexo AB 47
D-Pharm Ltd. 48
MIKA Pharma GmbH 49
Ache Laboratorios Farmaceuticos S/A 50
CoLucid Pharmaceuticals, Inc. 51
Pantarhei Bioscience BV 52
NeurAxon, Inc. 53
Winston Pharmaceuticals, Inc. 54
The EMMES Corporation 55
iCeutica, Inc. 56
Migraine – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 62
Drug Profiles 65
AZ-104 - Drug Profile 65
Levadex - Drug Profile 66
Levadex - Drug Profile 68
Levadex - Drug Profile 70
EUR 1000 - Drug Profile 72
BF-1 - Drug Profile 73
MK49 - Drug Profile 75
Sumatriptan SDI - Drug Profile 76
OX641 - Drug Profile 77
Estetrol - Drug Profile 78
INT-0008 - Drug Profile 80
Zolmitriptan - Drug Profile 81
MT 400 - Drug Profile 82
NXN-188 - Drug Profile 84
NXN-462 - Drug Profile 85
nNOS/NET - Drug Profile 86
VR-147 - Drug Profile 87
Nasal Carbon Dioxide - Drug Profile 88
NVD-201 - Drug Profile 89
LLL-2011 - Drug Profile 90
DP-VPA - Drug Profile 91
Candesartan Cilexitil - Drug Profile 93
BGG-492 - Drug Profile 94
LY2951742 - Drug Profile 96
Metoclopramide - Drug Profile 97
Zelrix - Drug Profile 98
COL-144 - Drug Profile 100
Topiramate + Propranolol - Drug Profile 101
N-Alpha Methyl Histamine - Drug Profile 103
Compazine - Drug Profile 105
Ethosuximide - Drug Profile 106
Metoclopramide + Ketoprofen - Drug Profile 107
BGC20-1531 - Drug Profile 108
Longevity Program - Drug Profile 109
DR-105 - Drug Profile 110
Ketoprofen - Drug Profile 111
MK-6096 - Drug Profile 112
Cyclobenzaprine Hydrochloride Extended Release - Drug Profile 113
Dolorac - Drug Profile 114
LY2300559 - Drug Profile 115
DIS-COM-TRO - Drug Profile 116
RHB-103 - Drug Profile 117
R101 - Drug Profile 118
Simvastatin + Vitamin D - Drug Profile 119
Naratriptan + Naproxen - Drug Profile 120
Topiramate - Drug Profile 121
Topiramate - Drug Profile 122
AP-1531 - Drug Profile 123
INT 1202 - Drug Profile 124
IO 1205 - Drug Profile 125
JWF1201 - Drug Profile 126
Migraine Therapeutics – Drug Profile Updates 127
Migraine Therapeutics – Discontinued Products 146
Migraine Therapeutics - Dormant Products 148
Migraine – Product Development Milestones 152
Featured News & Press Releases 152
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 160
Disclaimer 160
List of Tables
Number of Products Under Development for Migraine, H2 2012 13
Products under Development for Migraine – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Vyteris, Inc., H2 2012 29
Eli Lilly and Company, H2 2012 30
BioDelivery Sciences International, Inc., H2 2012 31
Merck & Co., Inc., H2 2012 32
Vectura Group plc, H2 2012 33
Alexza Pharmaceuticals, Inc., H2 2012 34
Biofrontera AG, H2 2012 35
Novartis AG, H2 2012 36
Axcan Pharma Inc., H2 2012 37
Dr. Reddy's Laboratories Limited, H2 2012 38
Teva Pharmaceutical Industries Limited, H2 2012 39
NuPathe Inc., H2 2012 40
Capnia, Inc., H2 2012 41
IntelGenx Technologies Corp., H2 2012 42
Lupin Limited, H2 2012 43
NovaDel Pharma, Inc., H2 2012 44
Paladin Labs Inc., H2 2012 45
MAP Pharmaceuticals, Inc., H2 2012 46
POZEN Inc., H2 2012 47
Asterand plc., H2 2012 48
Genizon BioSciences, Inc., H2 2012 49
Choongwae Pharma Corp, H2 2012 50
Orexo AB, H2 2012 51
D-Pharm Ltd., H2 2012 52
MIKA Pharma GmbH, H2 2012 53
Ache Laboratorios Farmaceuticos S/A, H2 2012 54
CoLucid Pharmaceuticals, Inc., H2 2012 55
Pantarhei Bioscience BV, H2 2012 56
NeurAxon, Inc., H2 2012 57
Winston Pharmaceuticals, Inc., H2 2012 58
The EMMES Corporation, H2 2012 59
iCeutica, Inc., H2 2012 60
Assessment by Monotherapy Products, H2 2012 61
Assessment by Combination Products, H2 2012 62
Assessment by Stage and Route of Administration, H2 2012 65
Assessment by Stage and Molecule Type, H2 2012 68
Migraine Therapeutics – Drug Profile Updates 131
Migraine Therapeutics – Discontinued Products 150
Migraine Therapeutics – Discontinued Products (Contd..1) 151
Migraine Therapeutics – Dormant Products 152
Migraine Therapeutics – Dormant Products (Contd..1) 153
Migraine Therapeutics – Dormant Products (Contd..2) 154
Migraine Therapeutics – Dormant Products (Contd..3) 155
List of Figures
Number of Products under Development for Migraine, H2 2012 13
Products under Development for Migraine – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 61
Assessment by Combination Products, H2 2012 62
Assessment by Route of Administration, H2 2012 63
Assessment by Stage and Route of Administration, H2 2012 64
Assessment by Molecule Type, H2 2012 66
Assessment by Stage and Molecule Type, H2 2012 67
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Migraine Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Migraine 9
Migraine Therapeutics under Development by Companies 11
Migraine Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Migraine Therapeutics – Products under Development by Companies 21
Migraine Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Migraine Therapeutics Development 25
Vyteris, Inc. 25
Eli Lilly and Company 26
BioDelivery Sciences International, Inc. 27
Merck & Co., Inc. 28
Vectura Group plc 29
Alexza Pharmaceuticals, Inc. 30
Biofrontera AG 31
Novartis AG 32
Axcan Pharma Inc. 33
Dr. Reddy's Laboratories Limited 34
Teva Pharmaceutical Industries Limited 35
NuPathe Inc. 36
Capnia, Inc. 37
IntelGenx Technologies Corp. 38
Lupin Limited 39
NovaDel Pharma, Inc. 40
Paladin Labs Inc. 41
MAP Pharmaceuticals, Inc. 42
POZEN Inc. 43
Asterand plc. 44
Genizon BioSciences, Inc. 45
Choongwae Pharma Corp 46
Orexo AB 47
D-Pharm Ltd. 48
MIKA Pharma GmbH 49
Ache Laboratorios Farmaceuticos S/A 50
CoLucid Pharmaceuticals, Inc. 51
Pantarhei Bioscience BV 52
NeurAxon, Inc. 53
Winston Pharmaceuticals, Inc. 54
The EMMES Corporation 55
iCeutica, Inc. 56
Migraine – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 62
Drug Profiles 65
AZ-104 - Drug Profile 65
Levadex - Drug Profile 66
Levadex - Drug Profile 68
Levadex - Drug Profile 70
EUR 1000 - Drug Profile 72
BF-1 - Drug Profile 73
MK49 - Drug Profile 75
Sumatriptan SDI - Drug Profile 76
OX641 - Drug Profile 77
Estetrol - Drug Profile 78
INT-0008 - Drug Profile 80
Zolmitriptan - Drug Profile 81
MT 400 - Drug Profile 82
NXN-188 - Drug Profile 84
NXN-462 - Drug Profile 85
nNOS/NET - Drug Profile 86
VR-147 - Drug Profile 87
Nasal Carbon Dioxide - Drug Profile 88
NVD-201 - Drug Profile 89
LLL-2011 - Drug Profile 90
DP-VPA - Drug Profile 91
Candesartan Cilexitil - Drug Profile 93
BGG-492 - Drug Profile 94
LY2951742 - Drug Profile 96
Metoclopramide - Drug Profile 97
Zelrix - Drug Profile 98
COL-144 - Drug Profile 100
Topiramate + Propranolol - Drug Profile 101
N-Alpha Methyl Histamine - Drug Profile 103
Compazine - Drug Profile 105
Ethosuximide - Drug Profile 106
Metoclopramide + Ketoprofen - Drug Profile 107
BGC20-1531 - Drug Profile 108
Longevity Program - Drug Profile 109
DR-105 - Drug Profile 110
Ketoprofen - Drug Profile 111
MK-6096 - Drug Profile 112
Cyclobenzaprine Hydrochloride Extended Release - Drug Profile 113
Dolorac - Drug Profile 114
LY2300559 - Drug Profile 115
DIS-COM-TRO - Drug Profile 116
RHB-103 - Drug Profile 117
R101 - Drug Profile 118
Simvastatin + Vitamin D - Drug Profile 119
Naratriptan + Naproxen - Drug Profile 120
Topiramate - Drug Profile 121
Topiramate - Drug Profile 122
AP-1531 - Drug Profile 123
INT 1202 - Drug Profile 124
IO 1205 - Drug Profile 125
JWF1201 - Drug Profile 126
Migraine Therapeutics – Drug Profile Updates 127
Migraine Therapeutics – Discontinued Products 146
Migraine Therapeutics - Dormant Products 148
Migraine – Product Development Milestones 152
Featured News & Press Releases 152
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 160
Disclaimer 160
List of Tables
Number of Products Under Development for Migraine, H2 2012 13
Products under Development for Migraine – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Vyteris, Inc., H2 2012 29
Eli Lilly and Company, H2 2012 30
BioDelivery Sciences International, Inc., H2 2012 31
Merck & Co., Inc., H2 2012 32
Vectura Group plc, H2 2012 33
Alexza Pharmaceuticals, Inc., H2 2012 34
Biofrontera AG, H2 2012 35
Novartis AG, H2 2012 36
Axcan Pharma Inc., H2 2012 37
Dr. Reddy's Laboratories Limited, H2 2012 38
Teva Pharmaceutical Industries Limited, H2 2012 39
NuPathe Inc., H2 2012 40
Capnia, Inc., H2 2012 41
IntelGenx Technologies Corp., H2 2012 42
Lupin Limited, H2 2012 43
NovaDel Pharma, Inc., H2 2012 44
Paladin Labs Inc., H2 2012 45
MAP Pharmaceuticals, Inc., H2 2012 46
POZEN Inc., H2 2012 47
Asterand plc., H2 2012 48
Genizon BioSciences, Inc., H2 2012 49
Choongwae Pharma Corp, H2 2012 50
Orexo AB, H2 2012 51
D-Pharm Ltd., H2 2012 52
MIKA Pharma GmbH, H2 2012 53
Ache Laboratorios Farmaceuticos S/A, H2 2012 54
CoLucid Pharmaceuticals, Inc., H2 2012 55
Pantarhei Bioscience BV, H2 2012 56
NeurAxon, Inc., H2 2012 57
Winston Pharmaceuticals, Inc., H2 2012 58
The EMMES Corporation, H2 2012 59
iCeutica, Inc., H2 2012 60
Assessment by Monotherapy Products, H2 2012 61
Assessment by Combination Products, H2 2012 62
Assessment by Stage and Route of Administration, H2 2012 65
Assessment by Stage and Molecule Type, H2 2012 68
Migraine Therapeutics – Drug Profile Updates 131
Migraine Therapeutics – Discontinued Products 150
Migraine Therapeutics – Discontinued Products (Contd..1) 151
Migraine Therapeutics – Dormant Products 152
Migraine Therapeutics – Dormant Products (Contd..1) 153
Migraine Therapeutics – Dormant Products (Contd..2) 154
Migraine Therapeutics – Dormant Products (Contd..3) 155
List of Figures
Number of Products under Development for Migraine, H2 2012 13
Products under Development for Migraine – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 61
Assessment by Combination Products, H2 2012 62
Assessment by Route of Administration, H2 2012 63
Assessment by Stage and Route of Administration, H2 2012 64
Assessment by Molecule Type, H2 2012 66
Assessment by Stage and Molecule Type, H2 2012 67
